US20040248132A1 - DR5 gene promoter and siah-1 gene promoter - Google Patents

DR5 gene promoter and siah-1 gene promoter Download PDF

Info

Publication number
US20040248132A1
US20040248132A1 US10/491,622 US49162204A US2004248132A1 US 20040248132 A1 US20040248132 A1 US 20040248132A1 US 49162204 A US49162204 A US 49162204A US 2004248132 A1 US2004248132 A1 US 2004248132A1
Authority
US
United States
Prior art keywords
dna
promoter
nucleotide sequence
gene
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/491,622
Other languages
English (en)
Inventor
Toshiyuki Sakai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolys Biopharma Inc
Original Assignee
Kansai Technology Licensing Organization Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kansai Technology Licensing Organization Co Ltd filed Critical Kansai Technology Licensing Organization Co Ltd
Assigned to KANSAI TECHNOLOGY LICENSING ORGANIZATION CO., LTD. reassignment KANSAI TECHNOLOGY LICENSING ORGANIZATION CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SAKAI, TOSHIYUKI
Publication of US20040248132A1 publication Critical patent/US20040248132A1/en
Assigned to ONCOLYS BIOPHARMA INC. reassignment ONCOLYS BIOPHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KANSAI TECHNOLOGY LICENSING ORGANIZATION CO., LTD.
Priority to US12/385,863 priority Critical patent/US8093368B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Definitions

  • the present invention relates to promoters for DR5 and Siah-1 genes, which are tumor suppression-related genes inducing apoptosis in cancer cells, to methods for screening for substances which regulate the activity of these promoters, and to substances obtained by these screening methods which regulate promoter activity.
  • p53 gene is a typical tumor suppressor gene which has been reported to be frequently mutated in human cancers.
  • p53 protein is known to be capable of suppressing onset and progress of cancer by acting as a transcription factor to transcriptionally activate target genes. More specifically, it is believed that when a mutation occurs in the genes of a normal cell and it starts to become tumorigenesis, p53 protein arrests the cell cycle at the G1 anaphase and performs DNA repair during that time, or when repair is impossible it destroys the incipient cancerous cells by apoptosis ( Kotsu Igaku 53 (5/6), 178-180, 1999).
  • DR5 (Death Receptor 5) is known as one protein whose transcription is induced by p53 protein and which is involved in p53-dependent apoptosis. DR5 induces apoptosis by binding a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). DR4, DcR1, and DcR2 are also known as TRAIL receptors. DcR1 and DcR2 have TRAIL-binding regions but lack active intracellular death regions and therefore do not induce apoptosis.
  • TNF tumor necrosis factor
  • TRAIL tumor necrosis factor-related apoptosis-inducing ligand
  • DR4 and DR5 include both TRAIL-binding regions and intercellular death regions, and they induce apoptosis through these intercellular death regions ( Science 277, 815-818 (1997)).
  • TRAIL exhibits selective toxicity for cancer cells over normal cells both in vitro and in vivo ( J. Biol. Chem . 271, 12687-12690). This is attributed to the fact that DcRs of TRAIL receptor genes are expressed more dominantly in normal cells than in cancer cells.
  • Siah-1 (seven in absentia homologue-1) is known as another protein whose transcription is induced by p53 ( EMBO J . 17, 2736-2747 (1998)). Siah-1 is activated by p53 protein to cause apoptosis and cell cycle arrest.
  • the protease complex proteasome is involved in Siah-1-induced apoptosis and cell cycle arrest.
  • the proteasome is an enzyme which recognizes ubiquitin in a ubiquitinated target protein and degrades the target protein.
  • Siah-1 binds to an enzyme part of which binds ubiquitin to a target protein, it activates the ubiquitin-binding enzyme and consequently promotes degradation of the target protein by the proteasome.
  • One target protein of the proteasome is the ⁇ -catenin protein, and degradation of ⁇ -catenin protein induces suppression of Cyclin D1, Myc and other genes expression, resulting in apoptosis and cell cycle arrest. ( Genes Dev . 11, 2701-2714 (1997), Genes Dev . 12, 1775-1780 (1998), Mol. Cell 7, 915-926 (2001)).
  • the inventors succeeded after much research in preparing a partial fragment of DR5 gene and a partial fragment of Siah-1 gene, and by using these fragments as probes to screen a human leukocyte genomic library, succeeded in isolating human DR5 gene promoter region and human Siah-1 gene promoter region. By preparing a series of deletion mutants for these promoter regions, they also discovered the regions that chiefly contribute to the promoter activity.
  • the present invention was completed based on the aforementioned findings, and provides the following respective promoter regions of the DR5 gene and Siah-1 gene, methods for screening for substances which regulate the activity of these promoters, and substances obtained by these screening methods which regulate promoter activity.
  • Item 1 A DNA of (a) or (b) below, or DNA which hybridizes under stringent conditions with this DNA and which functions as promoter;
  • a DNA comprising the nucleotide sequence of base numbers 1029-1034 or the nucleotide sequence of base numbers 1075-1080 together with the nucleotide sequence of up to 6 bases adjacent thereto and upstream therefrom and/or the nucleotide sequence of up to 6 bases adjacent thereto and downstream therefrom, of SEQ ID NO:1.
  • Item 2 A DNA of (c) or (d) below, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • Item 3 A DNA comprising at least one of the nucleotide sequences of base numbers 619-776, base numbers 777-1025 and base numbers 1026-1108 of SEQ ID NO:1, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • Item 4 A DNA comprising the nucleotide sequence of base numbers 1-1108 of SEQ ID NO:1, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • Item 5 A DNA comprising the nucleotide sequence of SEQ ID NO:1, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • Item 6 A DNA of (e) or (f) below, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • a DNA comprising the nucleotide sequence of base numbers 2219-2224 together with the nucleotide sequence of up to 6 bases adjacent thereto and upstream therefrom and/or the nucleotide sequence of up to 6 bases adjacent thereto and downstream therefrom, of SEQ ID NO:2.
  • Item 7 A DNA of (g) or (h) below, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • a DNA comprising any of the following nucleotide sequences together with the nucleotide sequence of up to 6 bases adjacent thereto and upstream therefrom and/or the nucleotide sequence of up to 6 bases adjacent thereto and downstream therefrom, of SEQ ID NO:2:
  • Item 8 A DNA comprising the nucleotide sequence of base numbers 2035-2382 of SEQ ID NO:2, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • Item 9 A DNA comprising the nucleotide sequence of SEQ ID NO:2, or a DNA which hybridizes under stringent conditions with this DNA and which functions as promoter.
  • Item 10 A method for screening for substances which regulate promoter activity, comprising a step of bringing a test substance into contact with cells containing a vector which comprises the DNA according to any of Items 1 to 9 together with a reporter gene capable of being expressed by this DNA, and a step of detecting changes in the expressed amount of the reporter gene due to contact with the test substance.
  • Item 11 A method for screening for substances which regulate promoter activity, comprising a step of introducing a test substance into cells containing a vector which comprises the DNA according to any of Items 1 to 9 together with a reporter gene capable of being expressed by this DNA, and a step of detecting changes in the expressed amount of the reporter gene due to introduction of the test substance.
  • Item 12 A method for screening for substances which regulate promoter activity, comprising a step of bringing a test substance into contact with the DNA according to any of Items 1 to 9, and a step of detecting a substance bound to this DNA.
  • Item 13 A method for screening for substances which regulate promoter activity, comprising a step of bringing a DNA-binding protein into contact with the DNA according to any of Items 1 to 9 with or without the presence of a test substance, and a step of detecting changes in the amount of binding of the DNA-binding protein to the DNA due to the presence of a test substance.
  • Item 14 A substance which regulates promoter activity obtained by the method according to any of Items 10 to 13.
  • Item 15 A vector comprising DNA according to any of Items 1 to 9 together with a reporter gene capable of being expressed by this DNA.
  • Item 16 Cells containing the vector of Item 15.
  • the inventors synthesized the two oligonucleotides 5′ CCGCAATCTCTGCGCCCACAAAATACACCG3′ (SEQ ID NO:3) and 5′ GTTTCAGCCCTTAAAGTAGATCGGGCATCG3′ (SEQ ID NO:4) based on the human DR5 gene sequence ( Science 277, 815-818 (1997)), and labeled these oligonucleotides with [ ⁇ - 32 p] using T4 polynucleotide kinase. The labeled oligonucleotides were used as probes for screening a human leukocyte genomic ⁇ PS library (Mol. Bio.
  • telomere sequence was determined by an ABI PRISM 310 Genetic Analyzer using a Big Dye Terminator Cycle Sequencing Kit (ABI PRISM, PE Applied Biosystems).
  • SacI-NcoI fragment the nucleotide sequence of a part of the 3′ end region containing the NcoI site is shown as SEQ ID NO:1.
  • This fragment contains the coding region of exon 1 (base numbers 1225-1368 of SEQ ID NO:1) and part of intron 1 (base numbers 1369-1654 of SEQ ID) of human DR5 gene, and these sequences matched the reported nucleotide sequence of human DR5 gene ( Science 277, 815-818 (1997)).
  • DNA comprising the nucleotide sequence of SEQ ID NO:1 or DNA which hybridizes under stringent conditions with this DNA and which functions as promoter is most desirable as the DR5 gene promoter of the present invention.
  • DNA consisting of the nucleotide sequence of SEQ ID NO:1 or DNA which hybridizes under stringent conditions with this DNA and which functions as promoter is especially desirable.
  • DNA having one or two or more bases substituted, deleted or added in DNA comprising the nucleotide sequence of SEQ ID NO:1 can be prepared by introduction of deletion using restriction enzyme or DNA exonuclease, introduction of mutation by site-specific mutagenesis, modification of the promoter sequence by PCR using mutant primer, direct introduction of synthetic mutant DNA and the like.
  • the promoter of the present invention may be prepared by known methods based on the nucleotide sequence of human DR5 gene. For example, as mentioned above, it can be obtained by a screening method with hybridization of a human genomic library using, as probe, an oligonucleotide synthesized based on the nucleotide sequence or base sequence of human DR5 gene: it can be also obtained by using the human genomic library as the PCR template, synthesizing the oligonucleotides of a sense primer corresponding to the vector DNA and an antisense primer corresponding to part of DR5 DNA, and combining them to perform PCR.
  • the human DR5 gene promoter of the present invention may comprise at least a nucleotide sequence of (1) or (2) below, or a nucleotide sequence which hybridizes under stringent conditions with the DNA of such a nucleotide sequence and which has promoter activity.
  • a nucleotide sequence which consists of at least a nucleotide sequence of (1) or (2) below or which hybridizes under stringent conditions with the DNA of such a nucleotide sequence and which has promoter activity is particularly desirable.
  • nucleotide sequences in SEQ ID NO:1 or a nucleotide sequence consisting of any of the following nucleotide sequences together with a nucleotide sequence of up to 6 bases adjacent to and upstream therefrom and/or a nucleotide sequence of up to 6 bases adjacent to and downstream therefrom, in SEQ ID NO:1.
  • these regions comprise transcription factor binding sites essential for promoter activity. That is, binding potential of the nucleotide sequence of SEQ ID NO:1 to known transcription factors was investigated by a computer search using TFSEARCH.
  • the known transcription factors that were used included GATA-1, AML-1a, c-Ets2, ADR1, c-Myb, SRY, Sp1, MZF1, CdxA, NFkB, p300, HSF2, Tst-1, Sox-5, Oct-1, GATA-1, Tst-1, Nkx-2, C/EBP ⁇ , deltaE, Ik-2, Elk-1, IRF-2, E47, SPY, STAT, USF, GATA-3, TATA, c-Rel and the like.
  • the search revealed that all the DNA regions above are regions capable of binding with any of these transcription factors.
  • DNA comprising these nucleotide sequences together with the nucleotide sequences adjacent to and up to 6 bases upstream therefrom may also bind to transcription factors.
  • DNA comprising these nucleotide sequences together with the nucleotide sequences adjacent to and up to 6 bases upstream therefrom may also bind to transcription factors.
  • the DNA region indicated by base numbers 1029-1034 and the DNA region indicated by base numbers 1075-1080 are thought to be core promoter regions. This is because these two potential transcription factor binding sites are the sites closest to the initiation codon of the DR5 gene, and because when a site-directed mutagenesis is introduced into these two sites in a luciferase reporter plasmid ligated with promoter DNA comprising these two potential transcription factor binding sites, the amount of luciferase expression declines significantly.
  • DNA comprising the nucleotide sequence of base numbers 1029-1034 or the nucleotide sequence of base numbers 1075-1080, or DNA comprising these nucleotide sequences together with the nucleotide sequences adjacent to and up to 6 bases upstream and/or adjacent to and up to 6 bases downstream therefrom is particularly preferable.
  • DNA consisting of the nucleotide sequence of base numbers 1029-1034 or the nucleotide sequence of base numbers 1075-1080, or DNA consisting of these nucleotide sequences together with the nucleotide sequences adjacent to and up to 6 bases upstream and/or adjacent to and up to 6 bases downstream therefrom is even more preferable.
  • the inventors synthesized the two oligonucleotides 5′ GACGGAGCGCGTTGGTGCCAGGACCGGGGT3′ (SEQ ID NO:5) and 5′ TTCCCGGCGCCGAGACCGACGGGACACCCT3′ (SEQ ID NO:6) comprising the DNA sequence of exon 1 of human Siah-1 gene based on the nucleotide sequence of human Siah-1 gene ( Genomics 46, 103-111 (1997)), and labeled these oligonucleotides with [ ⁇ - 32 P] using T4 polynucleotide kinase.
  • the labeled oligonucleotides were used as probes for screening a human leukocyte genomic ⁇ PS library (Mol. Bio. Tec., Gottinngen, Germany) to obtain an approximately 16.5 kb SacI-SacI fragment comprising exon 1 of human Siah-1 gene and its 5′-flanking region.
  • nucleotide sequence of this Kpn-1-NcoI fragment is shown in SEQ ID NO:2.
  • This fragment includes the 5′-flanking region of the human Siah-1 gene (part of exon 1; base numbers 2388-2515 of SEQ ID NO:2), and this sequence matched the reported nucleotide sequence ( Genomics 46, 103-111 (1997)) of the 5′-flanking region of human Siah-1 gene.
  • luciferase reporter plasmid pGVB2 (Nippon Gene Code No. 306-04831) comprising the aforementioned 2515 bp Kpn-1-NcoI fragment was transfected into MCF-7 cells in which Siah-1 gene is constantly expressed (National Institute of Health Sciences Cell Bank, JCRB0134), and luciferase activity of MCF-7 cell lysate measured after a fixed culture time.
  • the results confirm that lysate of MCF-7 cells having the introduced plasmid exhibits luciferase activity, and that the Kpn-1-NcoI fragment has promoter activity.
  • DNA comprising the nucleotide sequence of SEQ ID NO:2 or DNA which hybridizes under stringent conditions with this DNA and which functions as promoter is most preferable as the Siah-1 gene promoter of the present invention.
  • DNA consisting of the nucleotide sequence of SEQ ID NO:2 or DNA which hybridizes under stringent conditions with this DNA and which functions as promoter is particularly preferable.
  • the promoter of the present invention may comprise at least a nucleotide sequence of (3) or (4) below, or a nucleotide sequence which hybridizes under stringent conditions with DNA of such a nucleotide sequence and which has promoter activity.
  • the promoter consisting of a nucleotide sequence of (3) or (4) below, or a nucleotide sequence which hybridizes under stringent conditions with DNA of such a nucleotide sequence and which has promoter activity is prefrable.
  • these regions comprises transcription factor binding sites essential for promoter activity. That is, the potential binding of the nucleotide sequence of SEQ ID NO:2 to known transcription factors was investigated by means of a computer search using TFSEARCH.
  • the known transcription factors GATA-1, C/EBP, SRY, cdxA, CREB, GATA2, GATA3, NFkB, Sp1, N-myc, v-Myb, E2F and the like were used. The results of the search showed that the above respective DNA regions had potential binding these transcription factors.
  • the adjacent DNA regions up to about 6 bases before and after these DNA regions may also contribute to binding transcription factors. That is, DNA comprising these nucleotide sequences together with the adjacent nucleotide sequences of up to 6 bases upstream therefrom (particularly DNA consisting of these nucleotide sequences together with the adjacent nucleotide sequences of up to 6 bases upstream therefrom), DNA comprising these nucleotide sequences together with the adjacent nucleotide sequences of up to 6 bases downstream therefrom (particularly DNA consisting of these nucleotide sequences together with the adjacent nucleotide sequences of up to 6 bases downstream therefrom) or DNA comprising these nucleotide sequences together with the adjacent nucleotide sequences of up to 6 bases upstream and downstream therefrom (particularly DNA consisting of these nucleotide sequences together with the adjacent nucleotide sequences of up to 6 bases upstream and downstream therefrom) also has potential binding to transcription factors.
  • the DNA region indicated by base numbers 2219-2224 is believed to be the core promoter region. This is deduced from the fact that when a site-directed mutagenesis is introduced into the DNA region indicated by base numbers 2219-2224 in a luciferase reporter plasmid ligated with promoter DNA comprising this DNA region, the amount of expressed luciferase is significantly lower.
  • DNA comprising the nucleotide sequence of base numbers 2219-2224 of SEQ ID NO:1 or DNA comprising this nucleotide sequence together with an adjacent nucleotide sequence up to 6 bases upstream therefrom and/or up to 6 bases downstream therefrom is particularly preferable.
  • DNA consisting of the nucleotide sequence of base numbers 2219-2224 of SEQ ID NO:1 or DNA consisting of this nucleotide sequence together with an adjacent nucleotide sequence up to 6 bases upstream therefrom and/or up to 6 bases downstream therefrom is even more preferable.
  • the promoter DNA of the present invention can be used for treating or preventing DR5 or Siah-1 protein deficiency, abnormal expression or the like due to mutations in vivo. That is, DR5 protein or Siah-1 protein can be expressed under normal control by inserting DR5 gene having the DR5 promoter DNA of the present invention or Siah-1 gene having the Siah-1 promoter of the present invention into a retrovirus, adenovirus, adeno-associated virus or other vector, or including it in a liposome or the like and introducing it into somatic cells, as a means of improving DR5 protein or Siah-1 protein deficiency, abnormal expression or the like.
  • the promoter DNA of the present invention is activated or suppressed by a specific stimulus, it will be possible to induce or suppress expression of a desired gene by constructing and introducing into somatic cells a vector or the like with the DNA of the present invention inserted upstream from the desired gene, and applying the stimulus.
  • a cytocidal gene as the desired gene, it is possible to selectively kill cells having the introduced promoter DNA of the present invention by specifically simulating the gene.
  • such use of the promoter DNA of the present can be applied to a wide range of decease such as cancer and the like, in which cells need to be killed.
  • DNA having the same nucleotide sequence as the promoter DNA of the present invention can competitively block binding of cellular DR5 promoter DNA or Siah-1 promoter DNA with proteins capable of binding to these promoters such as transcription factors.
  • this method can be used to stimulate DR5 or Siah-1 promoter activity.
  • this method can be used to inhibit DR5 or Siah-1 promoter activity.
  • DR5 or Siah-1 protein has the effect of causing apoptosis or cell cycle arrest
  • stimulation of DR5 or Siah-1 promoter activity is useful in the treatment of cell proliferation disorders including malignant tumors, arteriosclerosis, restenosis due to proliferation of the vascular endothelial cells following balloon coronary angioplasty, and the like.
  • suppression of DR5 or Siah-1 promoter DNA activity is useful in the treatment of disorders in which cell proliferation is needed, such as aplastic anemia, cirrhosis of the liver, myocardial infarction, cerebral infarction, wound healing, and the like.
  • the promoter DNA of the present invention can be used to screen substances which regulate promoter activity, through the use of reporter genes which can be expressed by this DNA. That is, the promoter DNA of the present invention can be used to screen substances which can regulate DR5 or Siah-1 gene at the transcription level when they act on the promoter DNA either directly by binding to the promoter DNA or indirectly by binding to a cell membrane receptor or intercellular protein.
  • Compounds which can transcriptionally activate DR5 or Siah-1 gene are useful in the treatment of cell proliferation disorders including malignant tumors, arteriosclerosis, restenosis due to proliferation of the vascular endothelial cells following balloon coronary angioplasty, and the like.
  • substances which can transcriptionally suppress DR5 or Siah-1 gene are effective in the treatment of disorders in which cell proliferation is needed, such as aplastic anemia, cirrhosis of the liver, myocardial infarction, cerebral infarction, wound healing and the likes.
  • test substances include a wide range of proteins, oligopeptides, DNAs encoding them, polysaccharides, low molecular weight compounds and the like. These may be isolated from nature or synthesized artificially. There are no particular limits on the kinds of such substances or their molecular weights, but from the standpoint of movement into cells, low molecular weight compounds are the most preferable.
  • an oligopeptide or protein is one which moves into cells to act on the promoter of the present invention, it may be used as a fused protein with a membrane permeable protein for therapeutic drug applications, with the membrane permeable mechanism of the membrane permeable protein being exploited to move it into the cells.
  • reporter genes can be used as reporter gene used in the screening methods described below.
  • known reporter genes include the luciferase gene, chloramphenicol-acetyl-transferase (CAT) gene, secretory alkaliphosphatase (SEAP), human growth hormone (hGH), ⁇ -glucuronidase (GUS), green fluorescent protein (GFP) and the like.
  • CAT chloramphenicol-acetyl-transferase
  • SEAP secretory alkaliphosphatase
  • hGH human growth hormone
  • GUS ⁇ -glucuronidase
  • GFP green fluorescent protein
  • the luciferase gene is most preferable because it is highly sensitive and its activity is easily measured.
  • reporter plasmids lacking an intrinsic promoter region or reporter plasmids lacking an intrinsic enhancer region.
  • luciferase plasmids include pT811uc, pS1uc2, pXP1/pXP2 (all Nordeen, 1988) and the like.
  • a commercial reporter plasmid can be used for the reporter gene, or it can be used being inserted into a known vector.
  • a plasmid vector, virus vector or the like may be used as vector.
  • the vector for transfecting animal cells is preferable.
  • Animal cell vectors that can be used include for example pUC18, pUC19, M13mp18, pBluescript, pBR322 and the like.
  • the amount of protein expressed in cell culture supernatant can be measured because they are secretory proteins, while for the other reporter proteins, the amount of expressed protein in a lysate of cells lysed with a surfactant or the like can be measured by a method suited to those proteins.
  • the expressed amount of luciferase gene can be measured by using a luminometer to detect fluorescence in cell lysate due to degradation of luciferin, which is catalyzed by luciferase. Fluorescence emitted by cells can also be detected using a luminometer.
  • reporter assays can be performed manually, but they can also be performed rapidly and easily using high throughput screening ( Soshiki Baiyo Kogaku (Tissue Culture Engineering) Vol. 23, No. 13, 521-524, U.S. Pat. No. 5,670,113), which is done automatically with a machine.
  • high throughput screening Soshiki Baiyo Kogaku (Tissue Culture Engineering) Vol. 23, No. 13, 521-524, U.S. Pat. No. 5,670,113
  • the first screening method of the present invention comprises a step of bringing a test substance into contact with cells holding a vector comprising DNA which includes the human DR5 or Siah-1 gene promoter region of the present invention (here and below, this may be a region comprising the minimum region required for promoter activity) and a reporter gene ligated expressibly to this DNA, and a step of detecting changes in the amount of expressed reporter gene due to contact with the test substance.
  • the cells used may be cells in which DR5 gene itself is normal but DR5 protein activity is reduced.
  • cells may be used in which Siah-1 protein activity is reduced.
  • cancer cells such as human osteosarcoma cell line Saos-2 (ATCC, HTB85), colon cancer cell line DLD-1, human breast cancer cell line MCF-7 (National Institute of Health Sciences Cell Bank, JCRB0134), human renal epithelial cell line 293 (ATCC, CRL1573), erythroleukemia cell line K562 (ATCC, CCL243) and the like which have recognized p53 mutations can be used.
  • cells can be selected from a wide range of known cells such as Vero cells, HeLa cells, CV1 cells, Namalva cells, COS1 cells, CHO cells and the like.
  • the vector comprising a promoter region of the present invention and a reporter gene ligated so that it can be expressed by this promoter is as explained above.
  • This vector is preferably introduced constantly into cells.
  • contact of cells with the test substance can be accomplished for example as follows. Namely, cells holding the vector are passaged in a suitable medium for those cells, and cultured so that they reach the logarithmic growth phase. For contact with the test substance, the cells are seeded to about 20-30% confluence, and cultured for about 24 hours. Next, the test substance is added to the cell culture to a concentration of about 5 nM-50 ⁇ M. They are then incubated at about 37° C. for about 12-48 hours or preferably about 24 hours. A caspase inhibitor may be added in order to prevent the test substance from activating the promoter and inducing apoptosis.
  • the expressed amount of reporter gene can be measured by a method suited to the type of reporter gene.
  • the cells when using the luciferase gene as reporter gene, the cells can be lysed in a solvent containing a surfactant, and luciferase activity in the lysate can be measured by using a luminometer to detect luminescence due to degradation of luciferin.
  • the promoter When application of a test substance results in luciferase activity of about 50% or less that of the control, the promoter is considered suppressed. If luciferase activity is 200% or more that of the control, the promoter is considered activated.
  • test substance of this method There are no particular limits on the test substance of this method, and a wide range of proteins, oligopeptides, polysaccharides, low molecular weight compounds and the like can be used.
  • substances can be selected which affect activity of the promoter DNA of the present invention indirectly through cell membrane receptors or the like, as well as low molecular weight compounds which enter the cells and bind directly to the promoters of the present invention, and low molecular weight compounds which enter the cells and act indirectly on the promoters of the present invention by acting on intracellular proteins.
  • the second screening method of the present invention is a method comprising a step of introducing a test substance into cells holding a vector comprising DNA which includes the promoter region of the human DR5 or Siah-1 gene promoter region of the present invention and a reporter gene ligated expressibly to this DNA, and a step of detecting changes in the expressed amount of reporter gene due to contact with the test substance.
  • the cells and vectors and the methods for measuring the expressed amount of reporter gene are the same as for the first screening method.
  • a test substance can be temporarily introduced into the aforementioned cells by a method normally used for transfection such as the calcium phosphate method, DEAE-dextran method, electroporation method or liposome method, and changes can be detected in the expressed amount of reporter gene.
  • test substance is a protein
  • it can be introduced into cells as a fused protein together with a membrane permeable protein.
  • test substances screened by this method may include not only DNA but also proteins, oligopeptides, polysaccharides, low molecular weight compounds and the like.
  • the one-hybrid method can be given as another example of this method. Specifically, a reporter plasmid with the promoter DNA of the present invention inserted is introduced stably into cells, a gene library is then introduced therein, and proteins and the like which bind to the promoter DNA of the present invention are selected by selecting clones which exhibit promotion or suppression of reporter gene expression. With this method it is possible to obtain not only proteins and the like which bind directly to the promoter DNA of the present invention, but also proteins and the like which regulate the activity of the promoter DNA of the present invention indirectly by acting on intrinsic proteins and the like in the cells.
  • the one-hybrid method (Li J. J. and Herskowitz I., Science 262:1870-1873 (1993); Wang M. M. and Reed R. R., Nature 364:121-126 (1993)) can be carried out for example using a commercial kit such as the “Matchmaker System” (ClONTECH).
  • the third screening method of the present invention is a method comprising a step of bringing a test substance into contact with a DNA fragment comprising the human DR5 or Siah-1 gene promoter region of the present invention, and a step of detecting the substance bound to this DNA.
  • a promoter DNA fragment of normally 6 bp or more and preferably 18 bp or more can be used.
  • Affinity purification can be given as one example of this method.
  • the promoter DNA of the present invention is biotinylated and bound to magnetic beads having bound streptoavidin to prepare DNA affinity beads. Next, these are incubated with the test substance, and test substances which bind specifically to the promoter DNA of the present invention are purified and their structures are determined.
  • test substance which may be from a wide range including proteins, oligopeptides, polysaccharides, low molecular weight compounds and the like.
  • proteins proteins, oligopeptides, polysaccharides, low molecular weight compounds and the like.
  • a cell nucleus extract a cell nucleus extract, microorganism culture supernatant and the like can be used.
  • a nucleus extract is preferable because it includes a DNA binding protein such as a transcription factor.
  • test substance is a protein or the like
  • Southwestern blotting can be given as another example of this method. Specifically, a mixture of a protein or the like isolated by SDS-PAGE is transferred to a filter membrane and blotted directly with the promoter DNA of the present invention as probe, and protein or the like which binds to the DNA probe is selected.
  • Southwestern blotting is a method wherein a protein or the like is expressed in E. coli having an introduced gene library, then transferred to a filter membrane and blotted directly with the promoter DNA of the present invention as a probe, clones expressing the protein or the like are selected which bind to the DNA probe, and the genes encoding the protein are isolated. With this method it is possible to obtain both proteins or the like having binding activity with the DNA of the present invention and genes encoding the proteins.
  • Yet another example of this method is the gel shift method which is used when the test substance is a protein or the like. Specifically, a mixture of a protein or the like is mixed with a promoter DNA probe of the present invention labeled with an isotope or the like, it is subjected to polyacrylamide gel electrophoresis, and the bands of complexes of the protein or the like with the promoter DNA of the present invention in polyacrylamide gel are detected by the gel shift method. With this method it is possible to detect both proteins or the like which bind directly to the promoter DNA of the present invention and proteins or the like which bind indirectly to the promoter DNA of the present invention by binding with this protein or the like.
  • the fourth screening method of the present invention comprises a step in which DNA-binding protein is brought into contact with a DNA fragment comprising the human DR5 or Siah-1 gene promoter region of the present invention in the presence or in the absence of a test substance, and a step in which differences in the amount of binding of the DNA-binding protein to the DNA depending on the presence or absence of the test substance are detected.
  • Transcription factors and other proteins which are expected from a computer search to bind to the promoter DNA fragments used for screening can be used as the DNA-binding protein.
  • the gel shift method explained above can be given as an example of this method. Specifically, a DNA-binding protein and a labeled promoter DNA probe are bound together in the presence or in the absence of a test substance, and substances selected which either promote or suppress formation of the band for a composite of the DNA-binding protein and the promoter DNA of the present invention. In this way it is possible to select substances which do not directly bind to the promoter of the present invention but which promote or suppress binding of DNA-binding protein to promoter DNA.
  • a protein or the like which binds to the promoter DNA of the present invention is one which inhibits the activity of the promoter DNA of the present invention in the body, it is considered that a substance which inhibited binding of this protein or the like with the promoter DNA of the present invention can promote the activity of the promoter DNA of the present invention.
  • a protein is purified having glutathione S-transferase fused with a DNA-binding protein which is expected to bind to the promoter DNA of the present invention, the fused protein is bound to microplates covered with anti-glutathione S-transferase antibody, biotinylated promoter DNA of the present invention is brought into contact with the fused protein, and binding of the fused protein to the promoter DNA of the present invention is detected streptavidinated alkaliphosphatase.
  • the test substance is also added, and substances are selected which promote or suppress binding of the fused protein to the promoter DNA of the present invention.
  • a substance obtained by the aforementioned screening methods can be used as drug in the following forms.
  • composition can be used alone or prepared as a pharmaceutical composition by mixing with pharmacologically acceptable carriers (including excipients, extenders, binders, lubricants and the like) or conventional additives.
  • This pharmaceutical composition can be administered orally or parenterally depending on the form of preparation (tablets, pills, capsules, powders, granules, syrup or other orally administered form, injectable solution, drops, external preparation, suppository or other parenterally administered form) or the like.
  • the dosage will differ depending on the type of active constituent, administration route, subject of administration and patient age, weight, symptoms and the like and cannot be stipulated uniformly, but can be determined easily by a person having ordinary skill in the field.
  • the substance obtained is an oligopeptide or protein
  • it can be administered as a protein fused together with a membrane permeable protein.
  • the oligopeptide or protein can be transported into the cell by exploiting the membrane permeable mechanism of the membrane permeable protein.
  • DNA encoding this oligopeptide or protein can also be incorporated into a virus vector for gene therapy and introduced into the target cells.
  • the dosage and administration method will differ depending on the patient age, weight, symptoms and the like and cannot be stipulated uniformly, but can be determined easily by a person having ordinary skill in the field.
  • the substance obtained is a polynucleotide or oligonucleotide
  • it can be administered as drug in the form of the aforementioned pharmaceutical composition, or it can for example be enclosed in a liposome and introduced into cells by means of a liposome delivery system, microinjection, direct injection or a gene gun.
  • the dosage and administration method will differ depending on the patient age, weight, symptoms and the like and cannot be stipulated uniformly, but can be selected appropriately by a person having ordinary skill in the field.
  • it can also be incorporated into a virus vector for gene therapy or the like for introduction into the target cells.
  • the obtained substance is one which increases the expressed amount of DR5 gene or Siah-1 gene
  • a drug having the substance as its active ingredient is useful as a therapeutic or preventative drug for cell proliferation disorders such as malignant tumors, arteriosclerosis and restenosis due to proliferation of the vascular endothelial cells following balloon coronary angioplasty.
  • a drug having the substance as its active ingredient is useful as a therapeutic or preventative drug for disorders in which cell proliferation is needed, such as aplastic anemia, cirrhosis of the liver, myocardial infarction, cerebral infarction and wound healing.
  • Promoters for the tumor suppression-related genes human DR5 gene and human Siah-1 gene are provided by the present invention, thus allowing the activity of these promoters to be regulated and compounds which control expression of DR5 gene and Siah-1 gene to be screened.
  • p53 protein induces transcription of DR5 gene and Siah-1 gene, and contributes to suppressing cancer by causing apoptosis and cell cycle arrest. Because it seems that the expressed amount of DR5 and Siah-1 is often reduced in cancer cells rather than the proteins themselves being inactivated, a substance that could activate DR5 or Siah-1 gene at the transcription level by acting directly or indirectly on the promoters of the present invention is extremely useful for treating cancer and the like.
  • Human breast cancer cell line MCF-7 National Institute of Health Sciences Cell Bank, JCRB0134
  • human renal epithelial cell line 293 ATCC, CRL1573
  • human osteosarcoma cell line Saos-2 ATCC, HTB85
  • DMEM Dulbecco's modified Eagle medium
  • Erythroleukemia cells K562 ATCC, CCL243
  • RPMI 1640 medium Japan, Tokyo, Nissui, Code No. 05918
  • 10% fetal bovine serum and incubated in the same way.
  • oligonucleotides (CCGCAATCTCTGCGCCCACAAAATACACCG and GTTTCAGCCCTTAAAGTAGATCGGGCATCG) were synthesized based on the human DR5 nucleotide sequence ( Science 277, 815-818 (1997)), and used as probes for screening a human leukocyte genomic library. These probes were labeled with [ ⁇ - 32 P]ATP (Amersham Pharmacia Biotech, UK, Certificate No. 945784) and T4 polynucleotide kinase (Japan, Osaka, Toyobo, PNK-103). Labeling conditions were according to the manual for the T4 polynucleotide kinase.
  • phage plaques of a human leukocyte genome-derived ⁇ PS library (Mol. Biol. Tec., Germany, Product No. OB-4901-00, Funakoshi Catalogue) were screened using these probes in order to obtain genomic DNA fragments comprising the 5′-flanking region of human DR5 gene. Screening was performed according to the manual for the ⁇ PS library. Hybridization was performed for at least 16 hours at 50° C. in a buffer solution containing 5 ⁇ SSC, 0.1% SDS, 5 ⁇ Denhart's solution and 0.1 ⁇ g/ ⁇ l heat-denatured fish sperm DNA.
  • phage plaque was converted to a plasmid according to the manual for the ⁇ PS genome library (Mol. Biol. Tec., Germany, Product No. OB-4910-10, Funakoshi Catalogue), and its DNA was amplified and purified. Specifically, a single colony was grown overnight in LB broth, and plasmid DNA was extracted and purified using a QIAGEN kit (QIAGEN plasmid maxi kit (25), Cat. No. 12163, Germany).
  • genomic DNA fragment was treated with SacI, NcoI (Japan, Toyobo) and other restriction enzymes, and analyzed by Southern blotting (Laboratory Manual Genetic Engineering, Third Edition, Ed. Masami Muramatsu, pp. 73-76).
  • a sequence of 1654 bases including the 3′ end of this 2.5 kb SacI-NcoI fragment is shown by SEQ ID NO:1. This sequence includes part of exon 1 and the 5′-flanking region of DR5 gene, with the nucleotide sequence of part of exon 1 being identical to the reported sequence of human DR5 gene ( Science 277, 815-818 (1997)).
  • RNA probe was prepared with T7-RNA polymerase (MAXI script, Ambion) using, as template, a fragment (SmaI-ApaI fragment) comprising exon 1 of DR5 genome DNA subcloned into pBluescript.
  • Total RNA was also prepared from MCF-7 cells using Sepasol RNA I (Japan, Kyoto, nacalai-tesque Code No. 30655-36).
  • the RNA protection assay was carried out using an RPA III kit (Ambion) in accordance with the attached manual.
  • the nucleotide sequence of the resulting product was determined using a T7 Sequencing Kit (Amersham Pharmacia Biotech).
  • the 5′-flanking region (nucleotide sequence shown in sequence table) of DR5 gene was searched with a computer by TFSEARCH for potential binding to known transcription factors.
  • the transcription factors used in the search were GATA-1, AML-1a, c-Ets2, ADR1, c-Myb, SRY, Sp1, MZF1, CdxA, NFkB, p300, HSF2, Tst-1, Sox-5, Oct-1, GATA-1, Tst-1, Nkx-2, C/EBP ⁇ , deltaE, Ik-2, Elk-1, IRF-2, E47, SPY, STAT, USF, GATA-3, TATA and c-Rel.
  • nucleotide sequences were identified which may bind to known transcription factors. These are the nucleotide sequences shown by base numbers 102-108, 133-143, 149-162, 174-183, 196-210, 208-221, 211-220, 212-226, 222-231, 263-269, 265-278, 296-302, 377-383, 370-376, 409-420, 430-440, 431-436, 457-470, 458-470, 482-492, 498-507, 499-503, 500-505, 528-534, 536-541, 537-542, 542-547, 549-561, 555-567, 553-560, 559-566, 575-587, 593-598, 598-610, 601-610, 614-619, 618-623, 642-648, 650-656, 657-662, 683-697, 700-707, 742-747, 774-779, 785-798, 788-792
  • a series of 5′-deletion mutants of the promoter region of this invention was generated from pDR5/SacI using a “Kilo-sequence Deletion Kit” (Japan, Tokyo, Takara). These mutants are pDR5/37 comprising base numbers 37-1223, pDR5/619 comprising base numbers 619-1223, pDR5/777 comprising base numbers 777-1223, pDR5/1026 comprising base numbers 1026-1223, pDR5/1109 comprising base numbers 1109-1223 and pDR5/1186 comprising base numbers 1186-1223 in the sequence table.
  • MCF-7 cells (3 ⁇ 10 4 ) were seeded in 12-well tissue culture plates, and after 24 hours, 0.5 ⁇ g of the aforementioned plasmid was transiently transfected into the cells together with 0.4 ⁇ g of pAct ⁇ -gal containing the actin promoter-regulated ⁇ -galactosidase gene co-transfected in order to standardize transfection efficiency, using a Cell Phect Transfection kit (Amersham Pharmacia Biotech, 27-9268-01). After 48 hours, luciferase activity in cell lysate was measured according to the protocols of a Pica Gene luminescence kit (Toyo Ink, Tokyo, Japan, Code No.
  • transcription factor binding sites or enhancer sites essential for promoter activity of DR5 gene are present between base numbers 619-776, between base numbers 777-1025 and between base numbers 1026-1108 of SEQ ID NO:1.
  • pDR5mSp1-1 having an introduced substitution mutation in the region of base numbers 1029-1034 and pDR5mSp1-2 having an introduced substitution mutation in the region of base numbers 1075-1080 were prepared from luciferase reporter plasmid pDR5/1026 having inserted base numbers 1026-1223 of SEQ ID NO:1, using a QuickChange Site-Directed Mutagenesis Kit (Stratagene).
  • pDR5mTATA was prepared having an introduced substitution mutation in the TATA-like sequence of base numbers 1097-1103 in the sequence table.
  • the mutated reporter plasmids were transiently transfected into MCF-7 cells, and luciferase activity of the cell lysate was measured.
  • FIGS. 2 (A) and 2 (B) The nucleotide sequence and luciferase activity of each of the mutants are shown in FIGS. 2 (A) and 2 (B). From FIG. 2(B), it is clear that within the sequence of base numbers 1026-1223 (promoter region included in pDR5/1027) of SEQ ID NO:1 which contributes to promoter activity, the two Sp1 regions contribute chiefly to promoter activity, and that transcription binding sites or enhancer sites are present therein.
  • oligonucleotides (5′ GACGGAGCGCGTTGGTGCCAGGACCGGGGT3′ and 5′ TTCCCGGCGCCGAGACCGACGGGACACCCT3′) were synthesized based on the human Siah-1 sequence ( Genomics 46, 103-111 (1997)), and used as probes for screening a human leukocyte genomic library. These probes were labeled with [ ⁇ - 32 P]ATP (Amersham Pharmacia Biotech, UK, Certificate No. 945784) and T4 polynucleotide kinase (Japan, Osaka, Toyobo, PNK-103). Labeling conditions were according to the manual for the T4 polynucleotide kinase.
  • phage plaques of a human leukocyte genome-derived ⁇ PS library (Mol. Biol. Tec., Germany, product No. OB-4901-00, Funakoshi Catalogue) were screened using these probes in order to obtain genomic DNA fragments containing the 5′-flanking region of human Siah-1 gene. Screening was performed in accordance with the manual for the ⁇ PS phage genomic library. Hybridization was performed overnight at 50° C. in a buffer solution containing 5 ⁇ SSC, 0.1% SDS, 5 ⁇ Denhart's solution and 0.1 ⁇ g/ ⁇ l heat-denatured fish sperm DNA.
  • One positive phage plaque was converted to a plasmid according to the manual for the ⁇ PS genomic library, and its DNA was amplified and purified. Specifically, a single colony was grown overnight in LB broth, and plasmid DNA was extracted and purified using a QIAGEN kit (QIAGEN plasmid maxi kit (25), Cat. No. 12163, Germany).
  • the genomic DNA fragment was treated with KpnI, SacI, (Japan, Toyobo) and other restriction enzymes, and analyzed by Southern blot analysis (Laboratory Manual Genetic Engineering, Third Edition, Ed. Masami Muramatsu, pp. 73-76) using the oligonucleotides Siah-a and Siah-b.
  • This fragment comprises a 5′-flanking region (part of exon 1, base numbers 2388-2515 in SEQ ID NO:2) of human Siah-1 gene, and these sequences match the reported nucleotide sequence of the 5′-flanking region of human Siah-1 gene (Genomics 46, 103-111 (1997)).
  • the 5′-flanking region of Siah-1 gene (nucleotide sequence shown in sequence table) was searched with a computer by TFSEARCH for potential binding to known transcription factors.
  • the transcription factors used in the search were GATA-1, C/EBP, SRY, cdxA, CREB, GATA2, GATA3, NFkB, Sp1, N-myc, v-Myb and E2F.
  • nucleotide sequences were identified which may bind to known transcription factors. These are the nucleotide sequences shown in base numbers 95-104, 158-170, 272-278, 320-326, 362-368, 438-444, 568-575, 753-762, 1383-1391, 1438-1447, 1509-1515, 1613-1619, 1649-1660, 1715-1724, 1728-1737, 1789-1797, 1826-1832, 1889-1895, 2058-2069, 2074-2078, 2103-2107, 2209-2216, 2219-2224, 2302-2307 and 2317-2324 of SEQ ID NO:2.
  • a 2515 bp KpnI-NcoI fragment (base numbers 1-2515 in SEQ ID NO:2) containing the human Siah-1 promoter region obtained in Example 6 was subcloned into the KpnI-NcoI site of luciferase reporter plasmid pGVB2 (Japan, Tokyo, Nippon Gene). This plasmid was termed delKpnI.
  • a series of 5′-deletion mutants of the promoter region of this invention was generated from delKpnI using a “Kilo-sequence Deletion Kit” (Japan, Tokyo, Takara). These mutants are delPstI comprising base numbers 643-2515, delSmaI comprising base numbers 1290-2515, delalI comprising base numbers 1410-2515, delMluI comprising base numbers 1683-2515, delNheI comprising base numbers 2035-2515 and delXhoI comprising base numbers 2383-2515 in the sequence table.
  • MCF-7 cells (1 ⁇ 10 5 ) were seeded in diam. 3.5 cm tissue culture plates, and after a 1 day culture, 2 ⁇ g of the aforementioned plasmid was transfected into the cells by the DEAE-dextran method (CellPhect Transfection Kit, Amersham Pharmacia, Code No. 27-9268-01). After 48 hours, luciferase activity in cell lysate was measured according to the protocols of a Pica Gene luminescence kit (Toyo Ink, Tokyo, Japan, Code No. 309-04321), and standardized by protein concentration in the cell lysate. Each experiment was repeated three times, and each luciferase assay was triplicated. Significance was tested using a Student's t-test, and differences were considered significant when p ⁇ 0.05.
  • plasmid mSp1 having an introduced substitution mutation in the region of base numbers 2219-2224, plasmid mSp2 having an introduced substitution mutation in the region of base numbers 2302-2307, and plasmid mSp12 having introduced substitution mutations in both regions were prepared from luciferase reporter plasmid delNheI having inserted base numbers 2035-2515 of SEQ ID NO: 2, using a QuickChange Site-Directed Mutagenesis Kit (Stratagene) in accordance with the attached manual.
  • 5′-deletion mutants del-Sp1 having base numbers 2269-2515 and lacking the 5′-Sp1 site
  • del-Sp12 having base numbers 2311-2515 and lacking both Sp1 sites
  • luciferase reporter plasmid delNheI were prepared using a “Kilo Sequence Deletion Kit” (Takara).
  • the mutated reporter plasmids were transiently transfected into MCF-7 cells, and luciferase activity of the cell lysate was measured, as shown in Example 9-1.
  • Saos-2 cells were sampled 12, 24 and 32 hours after transfection, and total RNA extracted with Sepasol (nacalai tesque) reagent. Ten ⁇ g of each of extracted total RNAs was subjected to agarose gel electrophoresis, transferred to a filter, and hybridized with Siah-1 cDNA labeled with an isotope.
  • DR5 gene and Siah-1 gene are genes whose transcription is induced by p53 protein and which participate in suppression of cancer by causing apoptosis and cell cycle arrest. Consequently, the DR5 gene promoter and Siah-1 gene promoter of the present invention can be used favorably to screen substances which activate DR5 or Siah-1 gene at the transcription level by acting directly or indirectly thereon. Substances selected by the screening methods of the present invention are extremely effective for treatment of cancer and the like.
  • FIG. 1 shows changes in expressed amount of luciferase due to deletion mutations in the DR5 promoter region
  • FIG. 2 shows changes in expressed amount of luciferase due to mutations in Sp1 sites of the DR5 promoter.
  • A shows the nucleotide sequences of the mutants, while
  • B is a graph showing expressed amount of luciferase;
  • FIG. 3 shows changes in expressed amount of luciferase due to deletion mutations in the Siah-1 promoter region.
  • FIG. 4 shows changes in the expressed amount of luciferase due to mutations in Sp1 sites of the Siah-1 promoter.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US10/491,622 2001-10-04 2002-10-04 DR5 gene promoter and siah-1 gene promoter Abandoned US20040248132A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/385,863 US8093368B2 (en) 2001-10-04 2009-04-22 DR5 gene promoter and SIAH-1 gene promoter

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-309179 2001-10-04
JP2001309179 2001-10-04
PCT/IB2002/004074 WO2003038087A1 (fr) 2001-10-04 2002-10-04 Promoteur du gene dr5 et promoteur du gene siah-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/385,863 Division US8093368B2 (en) 2001-10-04 2009-04-22 DR5 gene promoter and SIAH-1 gene promoter

Publications (1)

Publication Number Publication Date
US20040248132A1 true US20040248132A1 (en) 2004-12-09

Family

ID=19128374

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/491,622 Abandoned US20040248132A1 (en) 2001-10-04 2002-10-04 DR5 gene promoter and siah-1 gene promoter
US12/385,863 Expired - Fee Related US8093368B2 (en) 2001-10-04 2009-04-22 DR5 gene promoter and SIAH-1 gene promoter

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/385,863 Expired - Fee Related US8093368B2 (en) 2001-10-04 2009-04-22 DR5 gene promoter and SIAH-1 gene promoter

Country Status (4)

Country Link
US (2) US20040248132A1 (ja)
EP (1) EP1439225A4 (ja)
JP (1) JPWO2003038087A1 (ja)
WO (1) WO2003038087A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117644A1 (en) * 2001-10-04 2011-05-19 Oncolys Biopharma Inc. DR5 gene promoter and SIAH-1 gene promoter
CN114958918A (zh) * 2022-06-24 2022-08-30 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种基于猪nlrp6基因启动子区的双荧光素酶报告基因载体及其构建方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2267097A1 (en) 1996-10-01 1998-04-09 Ercole Rao Human growth gene and short stature gene region
ES2281126T3 (es) * 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
JP2002506627A (ja) 1998-03-19 2002-03-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９５個のヒト分泌タンパク質
AU4817200A (en) * 1999-05-04 2000-11-17 Human Genome Sciences, Inc. Death domain containing receptor 5
US7465541B1 (en) 2000-01-21 2008-12-16 Toshiyuki Sakai Vitamin D3-responsive sequences located 5′-upstream of p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences
CA2395816A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins and antibodies
US20040248132A1 (en) * 2001-10-04 2004-12-09 Toshiyuki Sakai DR5 gene promoter and siah-1 gene promoter

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117644A1 (en) * 2001-10-04 2011-05-19 Oncolys Biopharma Inc. DR5 gene promoter and SIAH-1 gene promoter
US8093368B2 (en) * 2001-10-04 2012-01-10 Oncolys Biopharma Inc. DR5 gene promoter and SIAH-1 gene promoter
CN114958918A (zh) * 2022-06-24 2022-08-30 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种基于猪nlrp6基因启动子区的双荧光素酶报告基因载体及其构建方法与应用

Also Published As

Publication number Publication date
EP1439225A4 (en) 2005-10-26
EP1439225A1 (en) 2004-07-21
JPWO2003038087A1 (ja) 2005-02-24
US8093368B2 (en) 2012-01-10
US20110117644A1 (en) 2011-05-19
WO2003038087A1 (fr) 2003-05-08

Similar Documents

Publication Publication Date Title
White et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis
Kimura et al. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53
Watson et al. The ERGB/Fli-1 gene: isolation and characterization of a new member of the family of human ETS transcription factors
Bindra et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells
Rebollo et al. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors
Ulrix et al. The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells
Blanc et al. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model
CA2174354A1 (en) Compositions of melanoma differentiation associated gene-7 (mda-7) in cancer diagnosis and treatment
WO1997029213A1 (en) Coding sequences of the human brca1 gene
Santoro et al. Alternative splicing of the APC gene and its association with terminal differentiation
Li et al. Cloning of the rat β-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters
Wang et al. Effects of protein kinase Cα overexpression on A7r5 smooth muscle cell proliferation and differentiation
Ouatas et al. MMTV-associated transcription factor binding sites increase nm23-H1 metastasis suppressor gene expression in human breast carcinoma cell lines
Gueven et al. Site‐directed mutagenesis of the ATM promoter: consequences for response to proliferation and ionizing radiation
US8093368B2 (en) DR5 gene promoter and SIAH-1 gene promoter
US20110059899A1 (en) Kruppel-like factor 6 (KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein
US6537754B1 (en) Association of kinesin with sensitivity to chemotherapeutic drugs
Mora et al. Regulation of expression of the early growth response gene‐1 (EGR‐1) in malignant and benign cells of the prostate
RIETVELD et al. Dual role for transcription factor AP-2 in the regulation of the major fetal promoter P3 of the gene for human insulin-like growth factor II
Leśniak et al. Regulation of cell specific expression of calcyclin (S100A6) in nerve cells and other tissues
Voss et al. Mechanism of negative regulation of rat glutathione S-transferase A2 by the cytokine interleukin 6
Yang et al. Molecular cloning and structural characterization of the functional human thymosin β 4 gene
Matsumoto et al. Reduction of expression of the multidrug resistance protein (MRP) 1 in glioma cells by antisense phosphorothioate oligonucleotides
WO2000015780A1 (en) Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
Kurihara et al. Induction of p16/INK4a gene expression and cellular senescence by toyocamycin

Legal Events

Date Code Title Description
AS Assignment

Owner name: KANSAI TECHNOLOGY LICENSING ORGANIZATION CO., LTD.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAKAI, TOSHIYUKI;REEL/FRAME:015666/0406

Effective date: 20040329

AS Assignment

Owner name: ONCOLYS BIOPHARMA INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KANSAI TECHNOLOGY LICENSING ORGANIZATION CO., LTD.;REEL/FRAME:016594/0920

Effective date: 20050824

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION